| Literature DB >> 34878635 |
Benedikt Schaefgen1,2, Annika Funk1,2, H-P Sinn3,4, Thomas Bruckner5,6, Christina Gomez1,2, Aba Harcos1,2, Anne Stieber7,8, Annabelle Haller1,2, Juliane Nees1,2, Riku Togawa1,2, André Pfob1,2, André Hennigs1,2, Johanna Hederer1,2, Fabian Riedel1,2, Sarah Fastner1,2, Christof Sohn1,2, Jörg Heil1,2, Michael Golatta9,10.
Abstract
PURPOSE: This is the first study to systematically evaluate the diagnostic accuracy of intraoperative specimen radiography on margin level and its potential to reduce second surgeries in patients treated with neoadjuvant chemotherapy.Entities:
Keywords: Breast cancer; Breast conserving therapy; Intraoperative re-excision; Neoadjuvant chemotherapy; Specimen radiography; Surgical margins
Mesh:
Year: 2021 PMID: 34878635 PMCID: PMC8831236 DOI: 10.1007/s10549-021-06466-3
Source DB: PubMed Journal: Breast Cancer Res Treat ISSN: 0167-6806 Impact factor: 4.872
Fig. 1Flow diagram of patient population
Fig. 2Example of a conventional two-view specimen radiograph of a cCR patient. Marking wire and clipmarker are visible in the former tumor bed (a). In the twofold magnification of CSR, residual microcalcifications with insufficient margin width in the dorsal direction are visible, so re-excision was recommended in this direction (b). In contrast, the pathological workup showed a pCR (false positive CSR). The arrow indicates residual microcalcifications reaching the caudal margin
Patient and tumor characteristics
| Number of patients | ( |
|---|---|
| Age | |
| Mean | 51.4 (12.2) |
| Range | 24 to 82 |
| Ethnicity | not systematically assessed, mostly European |
| Cup size | |
| A | 5 (2.9) |
| B | 46 (26.4) |
| C | 26 (14.9) |
| D | 14 (8.0) |
| E | 2 (1.1) |
| F | 1 (0.6) |
| Unknown | 80 (45.4) |
| Menopausal status | |
| Premenopausal | 62 (35.6) |
| Menopausal | 22 (12.6) |
| Postmenopausal | 90 (51.7) |
| Breast density (ACR) | |
| A | 11 (6.3) |
| B | 82 (47.1) |
| C | 61 (35.1) |
| D | 20 (11.5) |
| Target structure for lesion marking | |
| Clip marker | 158 (90.8) |
| Clip marker detected in CSR | 154 (97.4) |
| Microcalcifications | 16 (9.2) |
| Radiographic presentation of the tumor | |
| Only mass | 126 |
| Mass with microcalcifications | 16 |
| Only microcalcifications | 2 |
| MRI performed | |
| Before and after NACT | 18 (10.3) |
| Only before NACT | 68 (39.1) |
| Only after NACT | 5 (2.8) |
| Remission status | |
| cCR | 85 (48.9) |
| With pCR (%) | 58 (68.2) |
| Non-cCR | 89 (51.1) |
| With pCR (%) | 25 (28.1) |
| Final T-stadium (ypT) | |
| 0 | 82 (47.1) |
| is | 11 (6.3) |
| 1 | 62 (35.6) |
| – 1mic | 1 (0.6) |
| – 1a | 19 (10.9) |
| – 1b | 14 (8.0) |
| – 1c | 28 (16.1) |
| 2 | 17 (9.8) |
| 3 | 1 (0.6) |
| 4 | – |
| Median specimen weight | |
| Primary resection | 38.0 g (range 5; 268) |
| Re-resection | 7.6 g (range 1; 41) |
| Histologically Infiltrated margins by orientation | |
| Total | 47 (4.5) |
| Medial | 3 (0.3) |
| Lateral | 3 (0.3) |
| Kranial | 14 (1.3) |
| Kaudal | 9 (0.9) |
| Ventral | 4 (0.4) |
| Dorsal | 14 (1.3) |
cCR clinical complete response, pCR pathological complete response
Evaluation of Conventional Specimen Radiography on a margin level for the whole and for patients with clinical complete response versus no clinical complete response
| Overall cohort | Clinical complete response (cCR) | No clinical complete response | Total––no. (%) | ||||
|---|---|---|---|---|---|---|---|
| CSR positive | CSR negative | CSR positive | CSR negative | CSR positive | CSR negative | – | |
| Reference test positive* | 9 | 38 | 1 | 9 | 8 | 29 | – |
| Reference test negative** | 108 | 889 | 51 | 449 | 57 | 440 | – |
| Total––no. (%) | 1044 (100%) | 510 (100%) | 534 (100%) | – | |||
| (95% CI) | (95% CI) | (95% CI) | |||||
| Sensitivity––% (95% CI) | 19.2% | (9.2–33.3%) | 10.0% | (0.3–44.5%) | 21.6% | (9.8–38.2%) | 0.660 |
| Specificity––% (95% CI) | 89.2% | (87.1–91.0%) | 89.8% | (86.8–92.3%) | 88.5% | (85.4–91.2%) | 0.542 |
| PPV––% (95% CI) | 7.7% | (3.6–14.1) | 1.9% | (0.1–10.3%) | 12.3% | (5.5–22.8%) | 0.076 |
| NPV––% (95% CI) | 95.9% | (94.4–97.1%) | 98.0% | (96.3–99.1%) | 93.8% | (91.2–95.8) | 0.001 |
| Margin conversion through CSR––no. (%) | 15 | (1.4%) | 1 | (0.2%) | 14 | (2.6%) | |
| NNT | 70 | 510 | 38 | ||||
cCR clinical complete response, CSR Conventional Specimen Radiography, NACT neoadjuvant chemotherapy, NNT number needed to treat, NPV negative predictive value, PMR positive margin rate, PPV positive predictive value
*Tumor infiltrated margin in histopathologic evaluation of the surgical specimen
**No tumor infiltrated margin in histopathologic evaluation of the surgical specimen
***For clinical complete response versus no clinical complete response
It shows the effect of CSR-guided re-resections on the final margin status and reduction of secondary surgeries on case level
| Overall cohort | cCR after NACT | Non-cCR after NACT | |
|---|---|---|---|
| Number of cases | 174 (100%) | 85 (100%) | 89 (100%) |
| Initial PMR | 25 (14.3%) | 7 (8.2%) | 18 (20.2%) |
| 13 (7.5%) | 3 (3.5%) | 10 (11.2%) | |
| 62 (35.6%) | 33 (38.8%) | 29 (32.6%) | |
| 87 (50.0%) | 45 (52.9%) | 42 (47.2%) | |
| 12 (6.9%) | 4 (4.7%) | 8 (9.0%) | |
| 52.0% (31.3–72.2%) | 42.9% (9.9–81.6%) | 55.6% (30.8–78.5%) | |
| 58.4% (50.0–66.4%) | 57.7% (46.0–68.8%) | 59.2% (46.8–70.7%) | |
| 17.3% (9.6–27.8%) | 8.3% (1.8–22.5%) | 25.6% (13.0–42.1%) | |
| 87.9% (79.8–93.6%) | 91.8% (80.4–97.7%) | 84.0% (70.9–92.8%) | |
| Final PMR | 17 (9.8%) | 6 (7.1%) | 11 (12.4%) |
| Conversion of margin status through CSR | 8 (4.6%) | 1 (1.1%) | 7 (7.9%) |
| NNT for conversion of margin status through CSR | 22 | 85 | 13 |
| Secondary surgeries | 16 (9.2%) | 6 (7.1%) | 10 (11.2%) |
| Number of secondary surgeries avoided through CSR | 7 (4%) | 1 (1.1%) | 6 (6.7%) |
| NNT to avoid secondary surgeries through CSR | 25 | 85 | 15 |
cCR clinical complete response, CSR Conventional Specimen Radiography, NACT neoadjuvant chemotherapy, NNT number needed to treat, PMR positive margin rate in histology
Analysis of CSR in Patients with and without NACT on margin level
| No NACTa | NACT | ||||
|---|---|---|---|---|---|
| Total margins | ( | (95% CI) | ( | (95% CI) | |
| Infiltrated margins | 310 (11.0%) | 47 (4.5%) | |||
| Sensitivity | 36.8% | (31.4–42.2%) | 19.1% | (9.2–33.3%) | 0.012* |
| Specificity | 86.8% | (85.5–88.1%) | 89.2% | (87.1–91.0%) | 0.055* |
| Positive predictive value (PPV) | 25.6% | (21.6–29.7%) | 7.7% | (3.6–14.1%) | < 0.001* |
| Negative predictive value (NPV) | 91.8% | (90.7–92.9%) | 95.9% | (94.4–97.1%) | < 0.001* |
CI confidence interval, NACT neoadjuvant chemotherapy
data from a previously published analysis[11]